CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.

The biopharmaceutical company reported adjusted earnings of 29 cents per share, topping the 25-cent consensus estimate. Revenue more than doubled year over year to $101.9 million, beating the $95.6 million consensus.

Revenue included $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio. DefenCath sales rose year over year, driven largely by the onboarding of a large dialysis organization in mid-2025.

Adjusted EBITDA jumped to $58.7 million from $22.4 million a year earlier.

CorMedix Advances REZZAYO Expansion Plans

On Thursday, CorMedix announced a collaboration with Mundipharma.

The company anticipates FDA submission of the sNDA for an expanded indication of REZZAYO for the prophylaxis of invasive fungal disease in the third quarter of this year.

Provided the application is accepted for FDA review, the company anticipates agency action on the application in the first half of 2027.

Reaffirms 2026 Sales Guidance

CorMedix reaffirmed its fiscal 2026 sales guidance of $325 million-$345 million compared to the Wall Street estimate of $334.089 million.

The company increased its adjusted EBITDA guidance to $125 million to $140 million, from $115 million to $135 million.

CRMD Technical Outlook: Key Levels And Momentum

The current price of $7.83 positions CorMedix Inc. 5.3% above its 20-day simple moving average (SMA) of $7.65, indicating a short-term bullish trend. However, the stock is trading 1.1% below its 50-day SMA of $8.15, suggesting potential resistance at that level.

The primary momentum indicator, MACD, is currently below its signal line, indicating that upside momentum is fading unless it can reclaim that baseline. This suggests that while the stock is experiencing a positive move today, the overall momentum may be cooling.

• Key Resistance: $9.00 — a nearby level where rebounds can stall, tied to a round-number area.
• Key Support: $7.00 — a nearby level where buyers previously stepped in, aligning with the 52-week low zone.

How CorMedix Ranks On Value And Momentum

Below is the Benzinga Edge scorecard for CorMedix, highlighting its strengths and weaknesses compared to the broader market:

• Value: 54.51 — The stock is moderately valued compared to its peers.
• Momentum: 9.53 — Stock is underperforming the broader market.

CRMD Stock Price Activity: Cormedix shares were up 10.28% at $7.83 during premarket trading on Thursday, according to Benzinga Pro data.

Photo: MacroEcon / Shutterstock.